3 recruiting, 2 completed, 1 active not recruiting, 1 terminated. 4 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Zymeworks BC Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ZW251 in Participants With Advanced Solid Tumors ZW251 - Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Zymeworks BC Inc. | 140 | 2025-10-21 | 2026-10-05 |
| A Study of ZW191 in Participants With Solid Tumors ZW191 - Advanced Solid Tumors | Phase 1 | Active not recruiting | Zymeworks BC Inc. | 145 | 2024-10-30 | 2026-05-07 |
| A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers ZW171 - Mesothelin-expressing Advanced Cancers | Phase 1 | Terminated | Zymeworks BC Inc. | 32 | 2024-09-30 | 2025-10-21 |
| Personalized Medicine for Advanced Biliary Cancer Patients Futibatinib, Ivosidenib, Zanidatamab - Biliary Tract Neoplasms | Phase 3 | Recruiting | UNICANCER | 800 | 2024-07-18 | 2026-05-19 |
| A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) Zanidatamab, Letrozole, Tamoxifen - Breast Cancer, HER2-positive | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 20 | 2021-11-16 | 2026-08-24 |
| ZW25 in Women With Endometrial Cancers ZW25 - Endometrial Cancer, Carcinosarcoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 16 | 2020-08-12 | 2025-05-22 |
| A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers ZW49 - HER2-expressing Cancers | Phase 1 | Completed | Zymeworks BC Inc. | 112 | 2019-04-15 | 2025-01-29 |
Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinosarcoma (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Lung Neoplasms (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Squamous Cell (1) · Ovarian Neoplasms (1) · Stomach Neoplasms (1)
zanidatamab (2) · Cisplatin (1) · Gemcitabine (1) · Letrozole (1) · Tamoxifen (1) · Trastuzumab (1) · binimetinib (1) · encorafenib (1) · futibatinib (1) · ivosidenib (1) · neratinib (1) · niraparib (1)
United States (6) · South Korea (3) · Australia (2) · Japan (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Ireland (1) · Portugal (1) · Singapore (1) · Taiwan (1)
Maggie Weinstein, MD, PhD, MPH (2) · Ivan Borbath, MD (1) · John Bridgewater, MD (1) · Joseph Woolery, PharmD, BCOP (1) · Juan W Valle (1) · Julien Edeline, MD (1) · Malka David, MD (1) · Pranshul Chauhan, MSc, MB, BCh, BAO (1) · Vicente Valero (1) · Vikky Makker, MD (1)
2025 (1)